FDA Approves Latisse For Hypotrichosis Treatment
The U.S. Food and Drug Administration (FDA) has approved LATISSE (bimatoprost ophthalmic solution) 0.03% as a novel treatment for hypotrichosis of the eyelashes. Eyelash hypotrichosis is another name for having inadequate or not enough eyelashes. LATISSE is the first and only FDA-approved, science-based treatment to enhance eyelash prominence as measured by increases in length, thickness and darkness of eyelashes.
Available only through a doctor, LATISSE is a once-daily prescription treatment applied to the base of the upper eyelashes with a sterile, single-use-per-eye disposable applicator. LATISSE users can expect to experience longer, fuller and darker eyelashes in as little as eight weeks, with full results in 16 weeks. To maintain effect, continued treatment with LATISSE is required. If use of LATISSE is discontinued, eyelashes will gradually return to where they were prior to treatment over a period of weeks to months (average eyelash hair cycle).
LATISSE will be available in the United States by prescription only and is subject to all U.S. guidelines applicable to dispensing a prescription medical product. Based on today's FDA approval, Allergan expects to launch the product nationwide in the first quarter of 2009.
LATISSE solution is intended for use on the skin of the upper eyelid margins at the base of the eyelashes. DO NOT APPLY to the lower eyelid. If you are using LUMIGAN or other products in the same class for elevated intraocular pressure (IOP), or if you have a history of abnormal IOP, you should only use LATISSE under the close supervision of your doctor.
LATISSE use may cause darkening of the eyelid skin which may be reversible. Although not reported in clinical studies, LATISSE use may also cause increased brown pigmentation of the colored part of the eye which is likely to be permanent.